Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,138.10 +100.88 0.67%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,220.40 +39.63 0.76%
  • Fund Type: Closed-End Fund
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: Global

BB Biotech AG

+ Add to Watchlist

BBZA:GR

97.4000 EUR 1.1000 1.14%

As of 13:49:09 ET on 05/17/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for BB Biotech AG (BBZA)

Open: 96.5300 High - Low: 97.4500 - 96.3500 Primary Exchange: Xetra
Volume: 12,089 52-Week Range: 57.6360 - 98.2500 Beta vs NBI: 0.7513

ETF Chart for BBZA

No chart data available.
  • BBZA:GR 96.8000
  • 1D
  • 1M
  • 1Y
96.3000
Interactive BBZA Chart

Previous Close

Fund Profile & Information for BBZA

BB Biotech AG is an investment company. The Company invests in biotech companies that operate in areas that include oncology, cardiovascular diseases, infectious diseases and autoimmune diseases.

Inception Date: 1993-11-09 Telephone: Tel: +41 44 267 67 00
Managers: DANIEL KOLLER
Web Site: www.bbbiotech.ch/en/bb-biotech/

Fundamentals for BBZA

NAV (on 2013-05-16) 122.7500
Assets (M) (on 2002-12-31) 1,579.0000
Shares out (M) 13.00
Market Cap (M) 1,266.20
% Premium -21.55
Average 52-Week % Premium -21.9412
Fund Leveraged N

Dividends for BBZA

Dividend Type Return of Capital
Dividend Frequency Annual
Last Dividend Net (on 2013-03-20) 4.5000
Dividend Yield (ttm) 3.78%

Performance for BBZA

1-Month +13.43% 1-Year +54.92%
3-Month +26.84% 3-Year +33.12%
Year To Date +39.86% 5-Year +18.01%
Expense Ratio 1.02

Top Fund Holdings for BBZA

Filing Date: 03/31/2012
Name Position Value % of Total
Celgene Corp 2,600,000 181,900,000 16.293%
Actelion Ltd 4,226,115 139,500,000 12.496%
Vertex Pharmaceuticals Inc 2,822,684 104,500,000 9.360%
Gilead Sciences Inc 4,220,000 93,000,000 8.330%
Incyte Corp Ltd 4,980,000 86,700,000 7.766%
Novo Nordisk A/S 591,056 73,900,000 6.619%
Isis Pharmaceuticals Inc 7,233,800 57,200,000 5.124%
Halozyme Therapeutics Inc 4,800,000 55,300,000 4.953%
Amylin Pharmaceuticals LLC 2,323,391 52,300,000 4.685%
ImmunoGen Inc 3,666,300 47,600,000 4.264%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil